Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
02 juil. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
01 juil. 2024 07h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Pharmaceutical Contract Manufacturing Market Report 2024-2030: Trends, Opportunities and Competitive Analysis Featuring Thermo Fisher Scientific, Catalent, Lonza, Almac Group, and Recipharm
21 juin 2024 09h44 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Manufacturing Market: Trends, Opportunities and Competitive Analysis (2024-2030)" report has been added to ...
ADC Contract Manufacturing Market, 2035 - Surging Demand for Antibody Drug Conjugates Driving Growth
20 juin 2024 04h02 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "ADC Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Stage of Development, Process Component, Target...
CKPT SHAREHOLDER ALERT: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT
23 mai 2024 12h38 HE
|
The Rosen Law Firm PA
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
23 mai 2024 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering
22 mai 2024 08h16 HE
|
BioConnection
AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering Strategic partnership provides a...
New Drug Approvals and Their Contract Manufacture 2024 Report - NDA Drug and Vaccine Approvals and the Levels of Outsourcing Associated with NDA Sub Segments
13 mai 2024 07h57 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "New Drug Approvals and Their Contract Manufacture - 2024 Edition" report has been added to ResearchAndMarkets.com's offering.This report is the 14th...
Avid Bioservices to Participate at Upcoming Investor Conferences
07 mai 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
24 avr. 2024 17h25 HE
|
Avid Bioservices, Inc
-- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion...